S
Shaanxi Meibang Pharmaceutical Group Co Ltd
SSE:605033
Shaanxi Meibang Pharmaceutical Group Co Ltd
SSE:605033
Price:
22.77
CNY
0.84%
Market Closed
Market Cap:
¥3.1B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
S
|
Shaanxi Meibang Pharmaceutical Group Co Ltd
SSE:605033
|
CN |
|
I
|
Infinity Natural Resources Inc
NYSE:INR
|
US |
|
Linc AB
STO:LINC
|
SE |
|
Studio Alice Co Ltd
TSE:2305
|
JP |
|
Hillstone Networks Co Ltd
SSE:688030
|
CN |
|
Polyrocks Chemical Co Ltd
SSE:688669
|
CN |
|
R
|
Rugvista Group AB (publ)
STO:RUG
|
SE |
|
Supermax Corporation Bhd
OTC:SPMXF
|
MY |
|
S
|
Shenzhen CDL Precision Technology Co Ltd
SZSE:300686
|
CN |
Income Statement
Earnings Waterfall
Shaanxi Meibang Pharmaceutical Group Co Ltd
Shaanxi Meibang Pharmaceutical Group Co Ltd
Income Statement
Shaanxi Meibang Pharmaceutical Group Co Ltd
Shaanxi Meibang Pharmaceutical Group Co Ltd
Currency: CNY
| Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ||||||||||||||
| Interest Expense |
3
|
3
|
2
|
1
|
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Revenue |
1 055
N/A
|
984
-7%
|
976
-1%
|
906
-7%
|
763
-16%
|
765
+0%
|
776
+1%
|
699
-10%
|
666
-5%
|
732
+10%
|
768
+5%
|
886
+15%
|
863
-3%
|
|
| Gross Profit | ||||||||||||||
| Cost of Revenue |
(624)
|
(567)
|
(560)
|
(529)
|
(453)
|
(465)
|
(486)
|
(478)
|
(467)
|
(523)
|
(542)
|
(654)
|
(618)
|
|
| Gross Profit |
431
N/A
|
417
-3%
|
416
0%
|
377
-9%
|
310
-18%
|
299
-4%
|
290
-3%
|
221
-24%
|
199
-10%
|
209
+5%
|
226
+8%
|
231
+2%
|
245
+6%
|
|
| Operating Income | ||||||||||||||
| Operating Expenses |
(258)
|
(251)
|
(258)
|
(243)
|
(203)
|
(203)
|
(185)
|
(177)
|
(185)
|
(206)
|
(220)
|
(203)
|
(243)
|
|
| Selling, General & Administrative |
(168)
|
(161)
|
(173)
|
(158)
|
(123)
|
(129)
|
(122)
|
(111)
|
(118)
|
(129)
|
(130)
|
(131)
|
(144)
|
|
| Research & Development |
(76)
|
(73)
|
(76)
|
(79)
|
(74)
|
(71)
|
(61)
|
(56)
|
(56)
|
(64)
|
(77)
|
(72)
|
(78)
|
|
| Depreciation & Amortization |
0
|
0
|
0
|
(6)
|
0
|
0
|
0
|
(11)
|
0
|
0
|
0
|
(12)
|
0
|
|
| Other Operating Expenses |
(13)
|
(17)
|
(10)
|
(0)
|
(5)
|
(2)
|
(2)
|
2
|
(11)
|
(12)
|
(14)
|
12
|
(22)
|
|
| Operating Income |
174
N/A
|
166
-4%
|
158
-5%
|
134
-15%
|
108
-20%
|
97
-10%
|
104
+8%
|
44
-58%
|
15
-67%
|
4
-76%
|
6
+69%
|
28
+365%
|
2
-93%
|
|
| Pre-Tax Income | ||||||||||||||
| Interest Income Expense |
1
|
3
|
4
|
6
|
5
|
5
|
5
|
6
|
6
|
8
|
9
|
10
|
9
|
|
| Gain/Loss on Disposition of Assets |
0
|
0
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
(0)
|
0
|
|
| Total Other Income |
16
|
26
|
27
|
12
|
13
|
4
|
3
|
12
|
11
|
12
|
12
|
0
|
8
|
|
| Pre-Tax Income |
191
N/A
|
194
+2%
|
190
-2%
|
152
-20%
|
125
-18%
|
105
-16%
|
112
+7%
|
62
-44%
|
32
-49%
|
24
-25%
|
27
+14%
|
38
+38%
|
19
-49%
|
|
| Net Income | ||||||||||||||
| Tax Provision |
(20)
|
(21)
|
(16)
|
(7)
|
(3)
|
(3)
|
(9)
|
(5)
|
1
|
7
|
3
|
(1)
|
3
|
|
| Income from Continuing Operations |
171
|
173
|
174
|
145
|
123
|
102
|
104
|
58
|
33
|
31
|
31
|
37
|
22
|
|
| Net Income (Common) |
171
N/A
|
173
+1%
|
174
+0%
|
145
-17%
|
123
-15%
|
102
-17%
|
104
+2%
|
58
-44%
|
33
-43%
|
31
-4%
|
31
-2%
|
37
+20%
|
22
-39%
|
|
| EPS (Diluted) |
1.26
N/A
|
1.28
+2%
|
1.29
+1%
|
1.07
-17%
|
0.9
-16%
|
0.75
-17%
|
0.76
+1%
|
0.43
-43%
|
0.24
-44%
|
0.23
-4%
|
0.23
N/A
|
0.27
+17%
|
0.17
-37%
|
|
Switch to:
Switch to:
See Also
Discover More
